Clinical trials
Active, not recruiting Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
336 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 7 |
| 2014 | 10 |
| 2015 | 7 |
| 2016 | 11 |
| 2017 | 19 |
| 2018 | 27 |
| 2019 | 29 |
| 2020 | 21 |
| 2021 | 39 |
| 2022 | 36 |
| 2023 | 53 |
| 2024 | 28 |
| 2025 | 22 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 336 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 27 |
| AbbVie | 23 |
| Memorial Sloan Kettering Cancer Center | 14 |
| St. Jude Children's Research Hospital | 14 |
| National Cancer Institute (NCI) | 12 |
| AstraZeneca | 6 |
| Genmab | 6 |
| UNC Lineberger Comprehensive Cancer Center | 6 |
| Abramson Cancer Center at Penn Medicine | 5 |
| Amgen | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 336 |
| Carcinoma, Non-Small-Cell Lung | 30 |
| Neoplasm Metastasis | 27 |
| Breast Neoplasms | 26 |
| Colorectal Neoplasms | 23 |
| Lung Neoplasms | 18 |
| Lymphoma | 17 |
| Lymphoma, Non-Hodgkin | 17 |
| Melanoma | 17 |
| Recurrence | 17 |
Trials
Showing 1 to 25 of 336. Each trial links to its page on Pharma Observatory.
236 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.